Bruce & Co’s Supernus Pharmaceuticals SUPN Stock Holding History

Bruce & Co’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.17M	Buy	100,000 +17,895	+22%	+$911K	1.48%	24
2025 Q4	$4.08M	Hold	82,105	–	–	1.27%	21
2025 Q3	$3.92M	Hold	82,105	–	–	1.22%	24
2025 Q2	$2.59M	Hold	82,105	–	–	0.84%	24
2025 Q1	$2.69M	Hold	82,105	–	–	0.86%	24
2024 Q4	$2.97M	Hold	82,105	–	–	0.95%	24
2024 Q3	$2.56M	Hold	82,105	–	–	0.75%	24
2024 Q2	$2.2M	Hold	82,105	–	–	0.72%	25
2024 Q1	$2.8M	Hold	82,105	–	–	0.93%	22
2023 Q4	$2.38M	Hold	82,105	–	–	0.83%	22
2023 Q3	$2.26M	Hold	82,105	–	–	0.77%	24
2023 Q2	$2.47M	Hold	82,105	–	–	0.69%	25
2023 Q1	$2.97M	Sell	82,105 -10,000	-11%	-$385K	0.81%	22
2022 Q4	$3.29M	Sell	92,105 -30,000	-25%	-$1.04M	0.85%	21
2022 Q3	$4.13M	Sell	122,105 -80,000	-40%	-$2.6M	1.14%	18
2022 Q2	$5.84M	Sell	202,105 -20,000	-9%	-$573K	1.37%	16
2022 Q1	$7.18M	Sell	222,105 -180,000	-45%	-$5.52M	1.47%	17
2021 Q4	$11.7M	Hold	402,105	–	–	2.34%	14
2021 Q3	$10.7M	Hold	402,105	–	–	2.28%	15
2021 Q2	$12.4M	Hold	402,105	–	–	2.36%	14
2021 Q1	$10.5M	Hold	402,105	–	–	1.97%	16
2020 Q4	$10.1M	Buy	402,105 +50,000	+14%	+$1.08M	1.95%	14
2020 Q3	$7.34M	Hold	352,105	–	–	1.52%	16
2020 Q2	$8.36M	Hold	352,105	–	–	1.82%	15
2020 Q1	$6.33M	Hold	352,105	–	–	1.46%	20
2019 Q4	$8.35M	Buy	352,105 +204,047	+138%	+$4.96M	1.63%	21
2019 Q3	$4.07M	Hold	148,058	–	–	0.84%	21
2019 Q2	$4.9M	Hold	148,058	–	–	1.04%	21
2019 Q1	$5.19M	Hold	148,058	–	–	1.01%	21
2018 Q4	$4.92M	Hold	148,058	–	–	1.05%	20
2018 Q3	$7.45M	Sell	148,058 -10,000	-6%	-$494K	1.44%	20
2018 Q2	$9.46M	Sell	158,058 -20,000	-11%	-$1.04M	1.88%	19
2018 Q1	$8.15M	Hold	178,058	–	–	1.7%	19
2017 Q4	$7.09M	Hold	178,058	–	–	1.54%	19
2017 Q3	$7.12M	Buy	178,058 +143,477	+415%	+$6.21M	1.59%	18
2017 Q2	$1.49M	Sell	34,581 -30,000	-46%	-$1.07M	0.34%	34
2017 Q1	$2.02M	Sell	64,581 -100,000	-61%	-$2.68M	0.48%	32
2016 Q4	$4.16M	Hold	164,581	–	–	1.09%	22
2016 Q3	$3.79M	Sell	164,581 -60,000	-27%	-$1.36M	1.02%	21
2016 Q2	$4.57M	Hold	224,581	–	–	1.17%	19
2016 Q1	$3.42M	Sell	224,581 -30,000	-12%	-$391K	0.95%	20
2015 Q4	$3.42M	Sell	254,581 -140,000	-35%	-$2.17M	0.93%	23
2015 Q3	$5.54M	Sell	394,581 -300,000	-43%	-$5.58M	1.42%	22
2015 Q2	$11.8M	Hold	694,581	–	–	3.05%	9
2015 Q1	$8.33M	Hold	694,581	–	–	2.11%	14
2014 Q4	$5.76M	Buy	694,581 +294,581	+74%	+$2.48M	1.59%	18
2014 Q3	$3.48M	Buy	400,000 +300,000	+300%	+$2.71M	0.97%	24
2014 Q2	$1.09M	Buy	+100,000	New	+$891K	0.25%	46

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bruce & Co's SUPN Position: Q1 2026 in Review

Bruce & Co increased its Supernus Pharmaceuticals (SUPN) stake by 22% in Q1 2026, buying an estimated $911K and bringing the position to 100,000 shares worth $5.17M. The position accounts for 1.48% of the portfolio, ranked #24.

Bruce & Co first reported a position in SUPN in Q2 2014 and has held it in 48 quarters since. The position peaked at $12.4M in Q2 2021. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

Bruce & Co held 100,000 shares of Supernus Pharmaceuticals worth $5.17M as of Q1 2026.
Bruce & Co bought 17,895 Supernus Pharmaceuticals shares in Q1 2026, an estimated $911K.
Supernus Pharmaceuticals made up 1.48% of Bruce & Co's portfolio in Q1 2026, its #24 holding.
Bruce & Co first reported a position in Supernus Pharmaceuticals in Q2 2014 and has held it in 48 quarters since.
Bruce & Co's Supernus Pharmaceuticals position peaked at $12.4M in Q2 2021.
327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Bruce & Co's 13F filing for Q1 2026, filed 14 May 2026.